Krystal Biotech (KRYS) saw its KRYS analyst rating maintained at Buy while Jefferies raised the price target to $371 from $310 on February 17, 2026. This action keeps the stock in Buy territory but signals stronger near-term upside from Jefferies.
Jefferies also noted model updates tied to VYJUVEK revenue and margin assumptions. The market reaction showed a short-term pullback of -2.27% (-$6.68). Meyka AI provides this AI-powered market analysis with context for investors.
KRYS analyst rating update from Jefferies
Jefferies maintained Buy for Krystal Biotech on February 17, 2026 and raised its price target to $371 from $310. The research note emphasized improved commercial execution and margin expansion assumptions. The official summary appeared on TheFly.
KRYS analyst rating: what the $371 price target means
A $371 target implies meaningful upside from recent trading levels and frames analyst expectations. Jefferies raised the target based on updated revenue pacing and gross margin forecasts for VYJUVEK. Investors should view the price target as an analyst estimate, not a guarantee.
After the Jefferies note, KRYS showed a short-term decline of -2.27% (-$6.68) on the report timestamp. This is consistent with profit-taking after price target news and earnings context. Traders may see the maintained Buy as supportive, while longer-term investors should weigh execution risk.
Recent company context from the Q4 2025 call
Krystal’s Q4 2025 earnings call highlighted expanding VYJUVEK revenue and international rollout plans. Management cited 94% gross margin for VYJUVEK and plans to expand to 40+ countries. See the call transcript for details on commercial progress and guidance assumptions via Seeking Alpha.
Historical analyst coverage and trend
Analyst coverage of Krystal Biotech has been limited but focused. Jefferies’ move continues a pattern of cautious optimism from sell-side firms that track gene therapy commercial rollouts. Historically, price targets have ranged widely as commercial data and approval timelines evolved.
Meyka analysis, market cap, and graded view
Meyka AI rates KRYS with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Market capitalization stands at $8,346,640,400, which reflects expectations for commercial growth and pipeline value.
Final Thoughts
Jefferies’ February 17, 2026 action kept the KRYS analyst rating at Buy while lifting the price target to $371. That combination signals analyst confidence in Krystal Biotech’s commercial rollout and margin trajectory. Investors should note the short-term stock pullback of -2.27% (-$6.68) around the note and weigh execution risk against upside potential.
For investors, the maintained Buy is a confirmation rather than an upgrade. It supports a constructive longer-term view, but careful monitoring of VYJUVEK sales and international expansion is essential. Meyka AI rates KRYS with a grade of B+, reflecting relative strength and remaining uncertainties. These grades are not guarantees, and we are not financial advisors.
FAQs
What changed in the KRYS analyst rating on February 17, 2026?
Jefferies maintained the KRYS analyst rating at Buy on February 17, 2026 and raised the price target to $371 from $310, citing stronger revenue and margin updates.
How should investors interpret the new KRYS price target?
The $371 price target signals analyst upside based on updated assumptions. Investors should treat it as an estimate and monitor commercial execution and margin delivery.
Does the Jefferies note mean a KRYS upgrade or downgrade?
Jefferies did not upgrade or downgrade the KRYS analyst rating. They maintained Buy while increasing the price target, which is a positive signal without a formal rating change.
How does the Meyka grade affect KRYS analysis?
Meyka AI rates KRYS with a grade of B+. This grade reflects benchmark and sector comparisons, growth metrics, and analyst consensus but is not financial advice.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
